Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $38.72 USD
Change Today +1.01 / 2.68%
Volume 318.1K
BABY On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

natus medical inc (BABY) Snapshot

Open
$37.84
Previous Close
$37.71
Day High
$38.78
Day Low
$37.58
52 Week High
04/22/15 - $42.96
52 Week Low
05/9/14 - $23.40
Market Cap
1.3B
Average Volume 10 Days
264.4K
EPS TTM
$1.13
Shares Outstanding
32.9M
EX-Date
--
P/E TM
34.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for NATUS MEDICAL INC (BABY)

Related News

No related news articles were found.

natus medical inc (BABY) Related Businessweek News

No Related Businessweek News Found

natus medical inc (BABY) Details

Natus Medical Incorporated designs, manufactures, and markets newborn care and neurology healthcare products and services worldwide. It offers healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. Its neurology products comprise diagnostic electroencephalography and long-term monitoring products, electrodiagnostic monitoring products, diagnostic polysomnography monitoring products, diagnostic intraoperative monitoring products, and transcranial Doppler products. The company’s newborn care products include hearing screening products to screen the hearing in the newborn; brain injury products to diagnose the severity of brain injury, monitor the effectiveness of drug therapies, detect seizure activity and monitor general neurological status; and thermoregulation products to control the newborn environment, including incubators and warmers. Its newborn care products also comprise jaundice management products to measure bilirubin levels and treat jaundice; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages; and balance and mobility systems to diagnose and assist in treating balance disorders. The company serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in Pleasanton, California.

948 Employees
Last Reported Date: 03/16/15
Founded in 1987

natus medical inc (BABY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $650.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $365.0K
Vice President and General Manager of Neurolo...
Total Annual Compensation: $295.0K
Vice President and General Manager of Newborn...
Total Annual Compensation: $295.0K
Vice President of Medical Affairs, Quality & ...
Total Annual Compensation: $267.0K
Compensation as of Fiscal Year 2014.

natus medical inc (BABY) Key Developments

Natus Medical Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter and Revises Earnings Guidance for the Full Year 2015

Natus Medical Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported income from operations of USD 13,346,000, income before tax was USD 12,517,000 and net income of USD 8,597,000 or USD 0.26 diluted per share on revenue of USD 89,395,000 against income from operations of USD 9,387,000, income before tax was USD 9,699,000 and net income of USD 6,755,000 or USD 0.21 diluted per share on revenue of USD 85,624,000 for the same period a year ago. Non-GAAP net income was USD 10,274,000 or USD 0.31 diluted per share against USD 8,287,000 or USD 0.26 diluted per share for the same period a year ago. Non-GAAP operating profit was USD 15,139,000 against USD 11,688,000 for the same period a year ago. For the second quarter of 2015, the company expects revenue of USD 89.5 million to USD 91.5 million and non-GAAP earnings per share of USD 0.31 to USD 0.33. The company increased its non-GAAP earnings guidance for the full year 2015 and now expects to report non-GAAP earnings per share of USD 1.47 to USD 1.51, an increase from previous guidance of USD 1.42 to USD 1.46. Full year 2015 revenue guidance was increased to USD 376 million to USD 378 million compared to previous guidance of USD 373 million to USD 375 million.

Natus Medical Incorporated Receives 510(k) FDA Clearance for the Quantum High Channel Count Amplifier

Natus Medical Incorporated announced that it has received FDA 510(k) clearance for the Quantum amplifier; an innovative high channel count amplifier that has applications in epilepsy and seizure monitoring along with research applications. Quantum is the first amplifier in the market to offer up to 256 channels in a compact, wearable package. Quantum is also the first compact amplifier to feature up to 16 kHz sampling rates providing increased visibility of faster brain frequencies combined with a software controlled Digital Switch Matrix facilitating functional brain mapping through cortical stimulation and a dual data stream for an efficient clinical and research workflow. The Quantum amplifier combined with Natus Neuroworks software produce an enhanced user experience resulting in improved patient care.

Natus Medical Inc. to Report Q1, 2015 Results on Apr 22, 2015

Natus Medical Inc. announced that they will report Q1, 2015 results at 11:00 AM, US Eastern Standard Time on Apr 22, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BABY:US $38.72 USD +1.01

BABY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeuroMetrix Inc $1.24 USD -0.0592
Oxford Instruments PLC 967.50 GBp +37.50
View Industry Companies
 

Industry Analysis

BABY

Industry Average

Valuation BABY Industry Range
Price/Earnings 37.0x
Price/Sales 3.5x
Price/Book 3.5x
Price/Cash Flow 38.0x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATUS MEDICAL INC, please visit www.natus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.